{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:11:49Z","timestamp":1787699509468,"version":"build-2784847793"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","award":["Ipsen"],"award-info":[{"award-number":["Ipsen"]}],"id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate the dosimetry and pharmacokinetics of the novel radiolabelled somatostatin receptor antagonist [<jats:sup>177<\/jats:sup>Lu]Lu-satoreotide tetraxetan in patients with advanced neuroendocrine tumours (NETs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study was part of a phase I\/II trial of [<jats:sup>177<\/jats:sup>Lu]Lu-satoreotide tetraxetan, administered at a median cumulative activity of 13.0 GBq over three planned cycles (median activity\/cycle: 4.5 GBq), in 40 patients with progressive NETs. Organ absorbed doses were monitored at each cycle using patient-specific dosimetry; the cumulative absorbed-dose limits were set at 23.0\u00a0Gy for the kidneys and 1.5\u00a0Gy for bone marrow. Absorbed dose coefficients (ADCs) were calculated using both patient-specific and model-based dosimetry for some patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In all evaluated organs, maximum [<jats:sup>177<\/jats:sup>Lu]Lu-satoreotide tetraxetan uptake was observed at the first imaging timepoint (4\u00a0h after injection), followed by an exponential decrease. Kidneys were the main route of elimination, with a cumulative excretion of 57\u201366% within 48\u00a0h following the first treatment cycle. At the first treatment cycle, [<jats:sup>177<\/jats:sup>Lu]Lu-satoreotide tetraxetan showed a median terminal blood half-life of 127\u00a0h and median ADCs of [<jats:sup>177<\/jats:sup>Lu]Lu-satoreotide tetraxetan were 5.0\u00a0Gy\/GBq in tumours, 0.1\u00a0Gy\/GBq in the bone marrow, 0.9\u00a0Gy\/GBq in kidneys, 0.2\u00a0Gy\/GBq in the liver and 0.8\u00a0Gy\/GBq in the spleen. Using image-based dosimetry, the bone marrow and kidneys received median cumulative absorbed doses of 1.1 and 10.8\u00a0Gy, respectively, after three cycles.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>[<jats:sup>177<\/jats:sup>Lu]Lu-satoreotide tetraxetan showed a favourable dosimetry profile, with high and prolonged tumour uptake, supporting its acceptable safety profile and promising efficacy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>NCT02592707. Registered October 30, 2015.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-024-06682-1","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T01:01:40Z","timestamp":1711414900000},"page":"2428-2441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours"],"prefix":"10.1007","volume":"51","author":[{"given":"Seval Beykan","family":"Sch\u00fcrrle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Eberlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ansquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Mathieu","family":"Beauregard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Durand-Gasselin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Haug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat P.","family":"Lenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaunak","family":"Navalkissoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume P.","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Pais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Volteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"McEwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"issue":"10","key":"6682_CR1","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00259-014-2735-5","volume":"41","author":"G Paganelli","year":"2014","unstructured":"Paganelli G, et al. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging. 2014;41(10):1845\u201351. https:\/\/doi.org\/10.1007\/s00259-014-2735-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"6682_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000348394","volume":"97","author":"M Sansovini","year":"2013","unstructured":"Sansovini M, et al. Treatment with the radiolabelled somatostatin analog\u2009177Lu-Dotatate for advanced pancreatic neuroendocrine tumors. Neuroendocrinology. 2013;97(4):347\u201354. https:\/\/doi.org\/10.1159\/000348394.","journal-title":"Neuroendocrinology"},{"issue":"2","key":"6682_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, et al. Phase 3 trial of 177Lu-Dotatate for Midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"issue":"12","key":"6682_CR4","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/s1470-2045(14)70474-7","volume":"15","author":"P Hoskin","year":"2014","unstructured":"Hoskin P, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397\u2013406. https:\/\/doi.org\/10.1016\/s1470-2045(14)70474-7.","journal-title":"Lancet Oncol"},{"issue":"12","key":"6682_CR5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"issue":"9","key":"6682_CR6","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, et al. Joint EANM\/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50(9):2830\u201345. https:\/\/doi.org\/10.1007\/s00259-023-06255-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6682_CR7","doi-asserted-by":"publisher","unstructured":"Maghsoomi Z, et al. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review. BMC Cancer. 2021;21. https:\/\/doi.org\/10.1186\/s12885-021-08257-x.","DOI":"10.1186\/s12885-021-08257-x"},{"issue":"3","key":"6682_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s12149-021-01699-0","volume":"36","author":"A Inaki","year":"2022","unstructured":"Inaki A, et al. An open-label, single-arm, multi-center, phase II clinical trial of single-dose [(131)I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma. Ann Nucl Med. 2022;36(3):267\u201378. https:\/\/doi.org\/10.1007\/s12149-021-01699-0.","journal-title":"Ann Nucl Med"},{"issue":"1","key":"6682_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40658-020-0273-8","volume":"7","author":"A Chicheportiche","year":"2020","unstructured":"Chicheportiche A, et al. Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management. EJNMMI Phys. 2020;7(1):5. https:\/\/doi.org\/10.1186\/s40658-020-0273-8.","journal-title":"EJNMMI Phys"},{"key":"6682_CR10","first-page":"1","volume":"14","author":"ICRP","year":"1984","unstructured":"ICRP. Nonstochastic effects of ionizing radiation. ICRP publication 41. Ann ICRP. 1984;14:1\u201333.","journal-title":"Ann ICRP"},{"issue":"7","key":"6682_CR11","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00259-008-0761-x","volume":"35","author":"M Lassmann","year":"2008","unstructured":"Lassmann M, et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35(7):1405. https:\/\/doi.org\/10.1007\/s00259-008-0761-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"6682_CR12","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.2967\/jnumed.117.206649","volume":"59","author":"M Lassmann","year":"2018","unstructured":"Lassmann M, Eberlein U. The relevance of Dosimetry in Precision Medicine. J Nucl Med. 2018;59(10):1494. https:\/\/doi.org\/10.2967\/jnumed.117.206649.","journal-title":"J Nucl Med"},{"key":"6682_CR13","doi-asserted-by":"publisher","unstructured":"Hagmarker L, et al. Bone Marrow Absorbed Doses and Correlations with Hematologic Response During 177Lu-Dotatate treatments are influenced by image-based dosimetry method and presence of skeletal metastases. J Nucl Med. 2019;60(10):1406 https:\/\/doi.org\/10.2967\/jnumed.118.225235.","DOI":"10.2967\/jnumed.118.225235"},{"key":"6682_CR14","doi-asserted-by":"publisher","unstructured":"Ilan E, et al. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-Dotatate. J Nucl Med. 2015;56(2):177 https:\/\/doi.org\/10.2967\/jnumed.114.148437.","DOI":"10.2967\/jnumed.114.148437"},{"issue":"10","key":"6682_CR15","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1007\/s00259-023-06257-6","volume":"50","author":"R Alipour","year":"2023","unstructured":"Alipour R, et al. The relationship between tumour dosimetry, response, and overall survival in patients with unresectable neuroendocrine neoplasms (NEN) treated with (177)Lu DOTATATE (LuTate). Eur J Nucl Med Mol Imaging. 2023;50(10):2997\u20133010. https:\/\/doi.org\/10.1007\/s00259-023-06257-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6682_CR16","doi-asserted-by":"publisher","unstructured":"Eychenne R, et al. Overview of Radiolabeled somatostatin analogs for Cancer Imaging and Therapy. Molecules. 2020;25(17). https:\/\/doi.org\/10.3390\/molecules25174012.","DOI":"10.3390\/molecules25174012"},{"issue":"6","key":"6682_CR17","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00432-020-03181-2","volume":"146","author":"J Zhang","year":"2020","unstructured":"Zhang J, et al. The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2020;146(6):1533\u201343. https:\/\/doi.org\/10.1007\/s00432-020-03181-2.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"6682_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","volume":"105","author":"RJ Hicks","year":"2017","unstructured":"Hicks RJ, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues. Neuroendocrinology. 2017;105(3):295\u2013309.","journal-title":"Neuroendocrinology"},{"issue":"44","key":"6682_CR19","doi-asserted-by":"publisher","first-page":"16436","DOI":"10.1073\/pnas.0607761103","volume":"103","author":"M Ginj","year":"2006","unstructured":"Ginj M, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006;103(44):16436\u201341. https:\/\/doi.org\/10.1073\/pnas.0607761103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6682_CR20","doi-asserted-by":"publisher","unstructured":"Fani M, et al. Radiolabeled somatostatin Analogs-A continuously evolving class of Radiopharmaceuticals. Cancers (Basel). 2022;14(5). https:\/\/doi.org\/10.3390\/cancers14051172.","DOI":"10.3390\/cancers14051172"},{"issue":"1","key":"6682_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13550-016-0204-9","volume":"6","author":"S Beykan","year":"2016","unstructured":"Beykan S, et al. 177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model. EJNMMI Res. 2016;6(1):50. https:\/\/doi.org\/10.1186\/s13550-016-0204-9.","journal-title":"EJNMMI Res"},{"issue":"8","key":"6682_CR22","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.2967\/jnumed.114.138834","volume":"55","author":"D Wild","year":"2014","unstructured":"Wild D, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor Radionuclide Therapy: a pilot study. J Nucl Med. 2014;55(8):1248\u201352. https:\/\/doi.org\/10.2967\/jnumed.114.138834.","journal-title":"J Nucl Med"},{"issue":"23","key":"6682_CR23","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1158\/1078-0432.Ccr-19-1026","volume":"25","author":"D Reidy-Lagunes","year":"2019","unstructured":"Reidy-Lagunes D, et al. Phase I Trial of Well-differentiated neuroendocrine tumors (NETs) with radiolabeled somatostatin antagonist 177Lu-Satoreotide Tetraxetan. Clin Cancer Res. 2019;25(23):6939\u201347. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1026.","journal-title":"Clin Cancer Res"},{"key":"6682_CR24","doi-asserted-by":"publisher","unstructured":"Wild D, et al. A phase I\/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2023;51(1). https:\/\/doi.org\/10.1007\/s00259-023-06383-1.","DOI":"10.1007\/s00259-023-06383-1"},{"issue":"5","key":"6682_CR25","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"L Bodei","year":"2013","unstructured":"Bodei L, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800\u201316. https:\/\/doi.org\/10.1007\/s00259-012-2330-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 2","key":"6682_CR26","first-page":"S219","volume":"31","author":"EP Krenning","year":"1999","unstructured":"Krenning EP, et al. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. Italian J Gastroenterol Hepatol. 1999;31(Suppl 2):S219\u201323.","journal-title":"Italian J Gastroenterol Hepatol"},{"issue":"3","key":"6682_CR27","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.zemedi.2015.01.001","volume":"25","author":"P Kletting","year":"2015","unstructured":"Kletting P, et al. The NUKDOS software for treatment planning in molecular radiotherapy. Z Med Phys. 2015;25(3):264\u201374. https:\/\/doi.org\/10.1016\/j.zemedi.2015.01.001.","journal-title":"Z Med Phys"},{"issue":"6","key":"6682_CR28","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s00259-010-1422-4","volume":"37","author":"C Hindorf","year":"2010","unstructured":"Hindorf C, et al. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37(6):1238\u201350. https:\/\/doi.org\/10.1007\/s00259-010-1422-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"17","key":"6682_CR29","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.1088\/0031-9155\/52\/17\/009","volume":"52","author":"AC Traino","year":"2007","unstructured":"Traino AC, et al. Influence of total-body mass on the scaling of <\u2009i\u2009>\u2009S-factors for patient-specific, blood-based red-marrow dosimetry. Phys Med Biol. 2007;52(17):5231\u201348. https:\/\/doi.org\/10.1088\/0031-9155\/52\/17\/009.","journal-title":"Phys Med Biol"},{"issue":"6","key":"6682_CR30","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023\u20137.","journal-title":"J Nucl Med"},{"issue":"11","key":"6682_CR31","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.2967\/jnumed.120.258889","volume":"62","author":"RP Baum","year":"2021","unstructured":"Baum RP, et al. First-in-humans study of the SSTR antagonist 177Lu-DOTA-LM3 for peptide receptor Radionuclide Therapy in patients with metastatic neuroendocrine neoplasms: Dosimetry, Safety, and Efficacy. J Nucl Med. 2021;62(11):1571. https:\/\/doi.org\/10.2967\/jnumed.120.258889.","journal-title":"J Nucl Med"},{"key":"6682_CR32","unstructured":"European Medcines Agency. Assessment report EMA\/506460\/2017: Lutathera. 2017 [cited 2022 28 May 2022]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/lutathera-epar-public-assessment-report_en.pdf."},{"key":"6682_CR33","unstructured":"Health Sciences Authority. Summary Report of Benefit-Risk Assessment: Lutathera. 2020 [cited 2022 28 June 2022]; Available from: https:\/\/www.hsa.gov.sg\/docs\/default-source\/hprg-tpb\/summary-reports\/lutathera_summary-report_01june2020.pdf."},{"key":"6682_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s40336-023-00589-x","author":"A Nautiyal","year":"2023","unstructured":"Nautiyal A, Michopoulou S, Guy M. Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review. Clin Translational Imaging. 2023. https:\/\/doi.org\/10.1007\/s40336-023-00589-x.","journal-title":"Clin Translational Imaging"},{"key":"6682_CR35","first-page":"S33","volume":"45","author":"S Beykan","year":"2018","unstructured":"Beykan S, et al. OP-081 patient-specific dosimetry of 177Lu-DOTATATE peptide receptor radionuclide therapy with high activities. Eur J Nucl Med Mol Imaging. 2018;45:S33.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"6682_CR36","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","volume":"45","author":"U Garske-Rom\u00e1n","year":"2018","unstructured":"Garske-Rom\u00e1n U, et al. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45(6):970\u201388. https:\/\/doi.org\/10.1007\/s00259-018-3945-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6682_CR37","doi-asserted-by":"publisher","unstructured":"Bergsma H, et al. Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-Dotatate: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2018;59(3):452 https:\/\/doi.org\/10.2967\/jnumed.117.189712.","DOI":"10.2967\/jnumed.117.189712"},{"issue":"7","key":"6682_CR38","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s00259-009-1072-6","volume":"36","author":"F Forrer","year":"2009","unstructured":"Forrer F, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2009;36(7):1138. https:\/\/doi.org\/10.1007\/s00259-009-1072-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"6682_CR39","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/17474124.2019.1685381","volume":"13","author":"S Das","year":"2019","unstructured":"Das S, et al. 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2019;13(11):1023\u201331. https:\/\/doi.org\/10.1080\/17474124.2019.1685381.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"6682_CR40","unstructured":"Food and Drug Administration. NDA 208700. 2017 [cited 2022 28 June 2022]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/208700Orig1s000OtherR.pdf."},{"issue":"10","key":"6682_CR41","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/jlcr.3755","volume":"62","author":"R Mansi","year":"2019","unstructured":"Mansi R, Fani M. Design and development of the theranostic pair 177Lu-OPS201\/68Ga-OPS202 for targeting somatostatin receptor expressing tumors. J Label Compd Radiopharm. 2019;62(10):635\u201345. https:\/\/doi.org\/10.1002\/jlcr.3755.","journal-title":"J Label Compd Radiopharm"},{"issue":"12","key":"6682_CR42","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/bjc.2016.377","volume":"115","author":"A Childs","year":"2016","unstructured":"Childs A, et al. Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours. Br J Cancer. 2016;115(12):1540\u20137. https:\/\/doi.org\/10.1038\/bjc.2016.377.","journal-title":"Br J Cancer"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06682-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06682-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06682-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T06:06:55Z","timestamp":1718345215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06682-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["6682"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06682-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"assertion":[{"value":"2 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"<b>SBS, UE<\/b>: None to declare. <b>CA<\/b>: Received personal and consulting fees from Novartis\/AAA. <b>JMB<\/b>: Received honoraria and\/or consulting fees from Ipsen and Novartis\/AAA. <b>LDG<\/b>: Employee of Ipsen. <b>HG<\/b>: Received research grants from Abbvie, Intercept, ARLA Food for Health, and ADS AIPHIA Development Services. <b>AH<\/b>; Received consulting fees from Ipsen, NOVO, and Pfizer; lectures for AstraZeneca and EISAI; and serves on the Data Monitoring Committee at IQVIA. <b>RJH<\/b>: Has shares in Telix Pharmaceuticals. <b>NPL<\/b>: None to declare. <b>SN<\/b>: Received honoraria and\/or consulting fees from Ipsen and Novartis\/AAA. <b>GPN<\/b>: None to declare. <b>BP<\/b>: Consultant to Ariceum and was employed by Ipsen at the time of study initiation. <b>MV<\/b>: Employee of Ipsen. <b>DW<\/b>: Received personal fees from Ipsen and grants from Siemens Healthineers. <b>AM<\/b>: Employee of Ariceum and was employed by Ipsen at the time of study initiation. <b>ML<\/b>: Received institutional grants from Ipsen, Nordic Nanovector, Novartis and PentixaPharm.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"All procedures involving human participants were carried out in accordance with the ethical standards of the institutional and\/or national research committees and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This article does not contain any experiments with animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}